US Pharma MarketingIndustry seeks more clarity on commissioner
Pharma and rare disease advocates press FDA at public hearing on Makary Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking…
The pharma industry and rare disease advocates voiced concerns about the transparency and fairness of the Commissioner's National Priority Voucher pilot program.
The program faces an uncertain future after former FDA Commissioner Marty Makary, who ...
Source: Endpoints News